These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34963678)

  • 1. Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    T A M; Chng R; Yau WP
    Ann Transplant; 2021 Dec; 26():e933588. PubMed ID: 34963678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence.
    Muduma G; Odeyemi I; Smith-Palmer J; Pollock RF
    Patient Prefer Adherence; 2014; 8():391-9. PubMed ID: 24729687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
    Rodríguez-Perálvarez M; Guerrero-Misas M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011639. PubMed ID: 28362060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
    Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
    Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?
    Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE
    Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized open-label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas-kidney patients.
    Cattral M; Luke S; Knauer MJ; Norgate A; Schiff J; Muirhead N; Luke PP
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29266398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
    Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
    Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation.
    Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G
    Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation.
    Trunečka P; Boillot O; Seehofer D; Pinna AD; Fischer L; Ericzon BG; Troisi RI; Baccarani U; Ortiz de Urbina J; Wall W;
    Am J Transplant; 2010 Oct; 10(10):2313-23. PubMed ID: 20840481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.
    Krämer BK; Charpentier B; Bäckman L; Silva HT; Mondragon-Ramirez G; Cassuto-Viguier E; Mourad G; Sola R; Rigotti P; Mirete JO;
    Am J Transplant; 2010 Dec; 10(12):2632-43. PubMed ID: 20840480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.